Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.64 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.61 |
| ▸ | CCR3 | P51677 | 1/20 | 0.61 |
| ▸ | BCHE | P06276 | 2/20 | 0.59 |
| ▸ | ACHE | P22303 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9538343 | 0.98 | GAA (0.63) | GAACXCR4CCR3BCHEACHE | |
| Hydrochloric Acid SCHEMBL9373038 | 0.98 | GAA (0.63) | GAACXCR4CCR3BCHEACHE | |
| SCHEMBL6747206 | 0.87 | CXCR4 (0.65) | GAACXCR4CCR3BCHEACHE | |
| Hydrochloric Acid SCHEMBL9537230 | 0.86 | BCHE (0.63) | GAACXCR4CCR3BCHEACHE | |
| SCHEMBL4702875 | 0.85 | SIGMAR1 (0.52) | ACHE | |
| SCHEMBL8006204 | 0.85 | CCR3 (0.63) | CCR3ACHE | |
| SCHEMBL26096555 | 0.85 | ACHE (0.72) | GAACCR3BCHEACHE | |
| SCHEMBL4505679 | 0.84 | ACHE (0.63) | CXCR4CCR3BCHEACHE | |
| SCHEMBL15338755 | 0.84 | CXCR4 (0.61) | GAACXCR4CCR3BCHEACHE | |
| Hydrochloric Acid SCHEMBL8825453 | 0.84 | BCHE (0.62) | GAACXCR4CCR3BCHEACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7462613-B2 | Pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-12-09 | — | — | US | claimed |
| EP-1817294-A1 | 1,2,3,4-TETRAHYDROPYRAZIN-2-YL ACETAMIDES AND THEIR USE AS BRADYKININ ANTAGONISTS FOR THE TREATMENT OF INFLAMMATION RELATED DISORDERS | Amgen Inc. (US) | 2007-08-15 | — | — | EP | claimed |
| WO-2006019975-A1 | 1,2,3,4-TETRAHYDROPYRAZIN-2-YL ACETAMIDES AND THEIR USE AS BRADYKININ ANTAGONISTS FOR THE TREATMENT OF INFLAMMATION RELATED DISORDERS | AMGEN INC. (US) | 2006-02-23 | — | — | WO | claimed |
| EP-3946416-A2 | AGONISTS OF ADIPONECTIN | Bayer Aktiengesellschaft (DE) | 2022-02-09 | — | — | EP | disclosed |
| CN-104955985-B | Etching solution, replenishment solution, and method for forming copper wiring | MEC股份有限公司 | 2018-07-20 | — | — | CN | disclosed |
| US-9643960-B2 | Procaspase activating compounds | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2017-05-09 | — | — | US | disclosed |
| US-9643960-B2 | Procaspase activating compounds | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2017-05-09 | — | — | US | disclosed |
| EP-2393794-B1 | DESIGN, SYNTHESIS AND EVALUATION OF PROCASPASE ACTIVATING COMPOUNDS AS PERSONALIZED ANTI-CANCER DRUGS | UNIV ILLINOIS (US) | 2017-03-22 | — | — | EP | disclosed |
| US-20150344452-A1 | PROCASPASE ACTIVATING COMPOUNDS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2015-12-03 | — | — | US | disclosed |
| US-20150344452-A1 | PROCASPASE ACTIVATING COMPOUNDS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2015-12-03 | — | — | US | disclosed |
| US-9102661-B2 | Design, synthesis and evaluation of procaspase activating compounds as personalized anti-cancer drugs | THE BOARD OF TRUSTEES OF THE UNIVERSITY ILLINOIS (US) | 2015-08-11 | — | — | US | disclosed |
| WO-2010091382-A1 | DESIGN, SYNTHESIS AND EVALUATION OF PROCASPASE ACTIVATING COMPOUNDS AS PERSONALIZED ANTI-CANCER DRUGS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2010-08-12 | — | — | WO | disclosed |
| US-7462613-B2 | Pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-12-09 | — | — | US | disclosed |
| US-7309701-B2 | Pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-12-18 | — | — | US | disclosed |
| EP-1611121-B1 | PYRIDAZINONE DERIVATIVES AS CDK2-INHIBITORS | AVENTIS PHARMA SA (FR) | 2007-08-08 | — | — | EP | disclosed |
| EP-1581505-B1 | PYRIDAZINONE DERIVATIVES AS GSK-3BETA INHIBITORS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2007-08-01 | — | — | EP | disclosed |
| EP-1056771-B1 | STREPTOGRAMIN DERIVATIVES, PREPARATION METHOD AND COMPOSITIONS CONTAINING SAME | AVENTIS PHARMA SA (FR) | 2005-11-30 | — | — | EP | disclosed |
| US-20050026918-A1 | Novel pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2005-02-03 | — | — | US | disclosed |
| EP-1056771-A1 | STREPTOGRAMIN DERIVATIVES, PREPARATION METHOD AND COMPOSITIONS CONTAINING SAME | Aventis Pharma S.A. (FR) | 2000-12-06 | — | — | EP | disclosed |
| WO-1999043699-A1 | STREPTOGRAMIN DERIVATIVES, PREPARATION METHOD AND COMPOSITIONS CONTAINING SAME | AVENTIS PHARMA S.A. (FR) | 1999-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150344452-A1 | PROCASPASE ACTIVATING COMPOUNDS | CASP3, CASP6, BAX | GAA 507/4885CXCR4 4372/4885CCR3 2944/4885 |
| US-20050026918-A1 | Novel pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them | C5, ADRA2C, ADRA1A | GAA 1977/4885CXCR4 2741/4885CCR3 1582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.